BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.

Authors

null

Maria Constantinou

Rhode Island Hosp Brown Univ, East Greenwich, RI

Maria Constantinou, Michael P. Vezeridis, Martin A. Weinstock, Joanna Walker, Thomas J. Miner, Peter Barth, Kayla Rosati, Kristen Mitchell, Sopha Dionson, Wendy Turchetti, John Vatkevich, William Matthew Rafelson, Kalyan C. Mantripragada, Howard Safran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT02656

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr TPS202)

DOI

10.1200/JCO.2018.36.5_suppl.TPS202

Abstract #

TPS202

Poster Bd #

N6

Abstract Disclosures